IL17A and neoplasm: In oncology, MAIT cells play paradoxical roles—they may exert limited antitumor effects in the early stages; however, the TME often induces high expression of inhibitory receptors, such as PD‐1 and TIM‐3, thereby driving the secretion of protumor factors, such as IL‐17 and IL‐8, and even suppressing other antitumor immune cells, ultimately turning accomplices of the tumor.